Gene clues could predict who benefits from cetuximab
NCT ID NCT01827956
First seen Jan 11, 2026 · Last updated Jun 11, 2026 · Updated 17 times
Summary
This study looked at whether certain genetic differences (polymorphisms) in immune receptors affect how well the cancer drug cetuximab works in people with advanced upper aerodigestive tract cancers. Researchers analyzed DNA from 121 patients to see if these gene variations could predict treatment response. The goal was to find biomarkers that could help personalize therapy, but this was an observational study, not a treatment trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER GINGIVAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Bergonié
Bordeaux, Aquitaine, 33000, France
Conditions
Explore the condition pages connected to this study.